Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Base Editing Gene Therapy for CD40L-HyperIgM Syndrome
NCT06959771Phase 2Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2025
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in Hyperimmunoglobulin M syndrome (HIGM), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Toxicities related to the infusion of the Study Cell Products and Percentages of corrected alleles. Started Jul 2025; status: recruiting.
02
Conditions
Hyperimmunoglobulin M syndrome (HIGM)
Beyond the preview
Go deeper on NCT06959771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06959771.